These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1029 related items for PubMed ID: 30396908

  • 21. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
    Zhang Y, Liang K, Zhou X, Zhang X, Xu H, Dai H, Song X, Yang X, Liu B, Shi T, Wei J.
    Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
    Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H, Jin Q, Su L, Liu X, Wang K, Yan G, Dong T, Wu S, Zhou P, Zhang J, Liang W, Ren J, Teng Y, Chen C, Xu XH.
    Mol Ther; 2019 Jun 05; 27(6):1114-1125. PubMed ID: 30962163
    [Abstract] [Full Text] [Related]

  • 28. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.
    Barber A, Meehan KR, Sentman CL.
    Gene Ther; 2011 May 05; 18(5):509-16. PubMed ID: 21209626
    [Abstract] [Full Text] [Related]

  • 29. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
    Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ, Río P, Martínez-López J.
    Blood Cancer J; 2021 Aug 14; 11(8):146. PubMed ID: 34392311
    [Abstract] [Full Text] [Related]

  • 30. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
    Pratap S, Zhao ZJ.
    Cancer Rep (Hoboken); 2020 Apr 14; 3(2):e1222. PubMed ID: 32671999
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
    Han Y, Xie W, Song DG, Powell DJ.
    J Hematol Oncol; 2018 Jul 06; 11(1):92. PubMed ID: 29980239
    [Abstract] [Full Text] [Related]

  • 34. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
    Märklin M, Hagelstein I, Koerner SP, Rothfelder K, Pfluegler MS, Schumacher A, Grosse-Hovest L, Jung G, Salih HR.
    J Immunother Cancer; 2019 May 29; 7(1):143. PubMed ID: 31142382
    [Abstract] [Full Text] [Related]

  • 35. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
    Yan L, Qu S, Shang J, Shi X, Kang L, Xu N, Zhu M, Zhou J, Jin S, Yao W, Yao Y, Chen G, Chang H, Zhu X, Yu L, Wu D, Fu C.
    Cancer Med; 2021 Jan 29; 10(2):563-574. PubMed ID: 33356013
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
    Li S, Tao Z, Xu Y, Liu J, An N, Wang Y, Xing H, Tian Z, Tang K, Liao X, Rao Q, Wang M, Wang J.
    Hum Gene Ther; 2018 May 29; 29(5):626-639. PubMed ID: 29409351
    [Abstract] [Full Text] [Related]

  • 38. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Story JY, Zoine JT, Burnham RE, Hamilton JAG, Spencer HT, Doering CB, Raikar SS.
    Cytotherapy; 2021 Jan 29; 23(1):12-24. PubMed ID: 33168453
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Current state and future prospects of CAR T-cell therapy for myeloid malignancies].
    Saito S.
    Rinsho Ketsueki; 2024 Jan 29; 65(7):634-643. PubMed ID: 39098014
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.